IE
SCLN

Israel Englander’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Israel Englander’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-85,935
Closed -$928K – 4086
2016
Q4 		$928K Sell
85,935
-122,320
-59% -$1.22M ﹤0.01% 2293
2016
Q3 		$2.13M Buy
+208,255
New +$2.27M ﹤0.01% 1900
2016
Q2 		– Sell
-738,789
Closed -$8.13M – 3847
2016
Q1 		$8.13M Buy
738,789
+264,756
+56% +$2.35M 0.02% 958
2015
Q4 		$4.36M Buy
474,033
+398,776
+530% +$3.34M 0.01% 1456
2015
Q3 		$522K Sell
75,257
-344,675
-82% -$2.95M ﹤0.01% 2636
2015
Q2 		$4.12M Sell
419,932
-101,200
-19% -$922K 0.01% 1508
2015
Q1 		$4.62M Buy
521,132
+253,082
+94% +$2.02M 0.01% 1453
2014
Q4 		$2.35M Buy
268,050
+102,844
+62% +$832K 0.01% 1865
2014
Q3 		$1.14M Buy
165,206
+102,159
+162% +$612K ﹤0.01% 2217
2014
Q2 		$332K Buy
63,047
+22,847
+57% +$111K ﹤0.01% 2825
2014
Q1 		$183K Sell
40,200
-369,568
-90% -$1.78M ﹤0.01% 3222
2013
Q4 		$2.06M Buy
409,768
+349,098
+575% +$1.68M 0.01% 1805
2013
Q3 		$308K Sell
60,670
-136,522
-69% -$760K ﹤0.01% 2851
2013
Q2 		$978K Buy
+197,192
New +$938K ﹤0.01% 1972

Other funds holding SCLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Israel Englander's SCLN Position: Q1 2017 in Review

Israel Englander sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 85,935 shares — an estimated $928K sold.

Israel Englander first reported a position in SCLN in Q2 2013 and held it in 14 quarters. The position peaked at $8.13M in Q1 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Israel Englander reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Israel Englander sold 85,935 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $928K.
  • Israel Englander first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 14 quarters.
  • Israel Englander's Sciclone Pharmaceuticals Inc position peaked at $8.13M in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Millennium Management's 13F filing for Q1 2017, filed 15 May 2017.